Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

HIVR4P 2016 is made possible in part by the generous support of the American people through 1 R13 AI122959-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services or USAID; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 sessions: 1 to 25 of 42
Opening Plenary: Get It and Forget It: Long-acting HIV Prevention
Welcome to HIVR4P 2016
Thomas Hope
Northwestern University, United States
The European Union's Research Strategy: Making an Impact on the HIV Epidemic
Ruxandra Draghia-Akli
European Commission, Belgium
Update on the Global HIV Vaccine Enterprise
William Snow
Global HIV Vaccine Enterprise
Congratulations to the 2016 Scholars
Maureen Goodenow
NIH Associate Director for AIDS Research and Director, Office of AIDS Research, United States
ART Prevents HIV Transmission: What Happens Next?
Myron Cohen
University of North Carolina, United States
Overview of Humoral and Cellular Immune Responses to HIV Vaccination
Georgia Tomaras
Duke University, United States
HIV Prevention Science in 2016: New Weapons in the Arsenal
Anthony Fauci
National Institute of Allergy and Infectious Diseases, NIH, United States
from HIV Research for Prevention 2016 on 17 October 2016 16:00-18:00
Plenary 02: Unraveling the Mysteries of HIV Transmission
HIV Transmission Dynamics
Deenan Pillay
Africa Health Research Institute, South Africa
Mechanisms of HIV Transmission: Implications for Prevention
Julie Overbaugh
Fred Hutchinson Cancer Research Center, United States
Providing Prevention Where It Matters Most: Data-informed Targeting of HIV Prevention and Care
Patrick Sullivan
Emory University Rollins School of Public Health, United States
from HIV Research for Prevention 2016 on 18 October 2016 08:30-10:00
Oral Abstract Session 01: Antibody Epitopes: Connecting the Dots
A Prominent Site of Antibody Vulnerability on HIV Env Incorporates the CCR5 Coreceptor Site and Its Camouflaging Glycans
Devin Sok
International AIDS Vaccine Initiative (IAVI), United States
HIV-1 MPER-directed Broadly Neutralizing Antibodies from an Acute-infection Cohort RV217 Subject
Nicole A. Doria-Rose
Vaccine Research Center, NIAID, NIH, United States
Persistence of an HIV Broadly Neutralizing Antibody Lineage Despite Complete Neutralization Escape
Jinal N Bhiman
National Institute for Communicable Diseases of the National Health Laboratory Services, South Africa
Viral Escape from HIV Broadly Neutralizing Antibodies Is Slower and More Complex than for Early Strain-specific Neutralizing Antibodies
Colin Anthony
University of Cape Town, South Africa
The Anti-gp120 mAb CH58 Recognizes a Not-fully-processed Form of Surface-expressed Env
Jason Yolitz
NIAID, NIH, United States
Fusion Peptide of HIV-1 as a Site of Vulnerability to Neutralizing Antibody
Rui Kong
Vaccine Research Center, NIAID, NIH, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 02: Crossing the Border: Mechanisms of Mucosal Transmission
Defining HIV/SIV Infection after Rectal Challenge in Rhesus Macaque Model Using Dual Reporter System
Danijela Maric
Northwestern University, United States
Broadly Neutralizing Antibodies Can Prevent HIV Infection in Foreskin Ex-vivo Explant Infection Models
Maria Lemos
Fred Hutchinson Cancer Research Center, United States
In Vivo Analysis of Fluorescently Tagged HIV-specific and Non-specific Antibodies in Non-human Primates
Ann M. Carias
Northwestern University, United States
HIV Susceptibility in CD4+ T Cells Derived from the Inner Versus Outer Foreskin
Ronald Galiwango
University of Toronto, Canada
Intestinal Dendritic Cells and Macrophages Differentially Affect HIV-1 Transmission Across the Intestinal Mucosa
Mariangela Cavarelli
CEA, France
Levels of Immune Activation in Cervical Cells, Rectal Cells and PBMCs Isolated from a Kenyan Women Cohort at Low-risk of HIV Acquisition
Catia Perciani
University of Toronto, Canada
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 03: PrEP Problems: Real and Imagined
The Effect of Oral Pre-exposure Prophylaxis on the Progression of HIV-1 Seroconversion
Deborah Donnell
Fred Hutchinson Cancer Research Center, United States
Infant Exposure to Tenofovir and Emtricitabine through Breast Milk when Used as Pre-exposure Prophylaxis by HIV-uninfected Lactating Women
Kenneth Mugwanya
University of Washington, United States
HIV-1 Resistance Outcomes in Seroconverters from the MTN-020/ASPIRE Dapivirine Vaginal Ring Study
Urvi M. Parikh
University of Pittsburgh, United States
Evaluation of Resistance to Cabotegravir Long-acting (CAB LA) in SIVmac251-infected Macaques
Chasity Andrews
Aaron Diamond AIDS Research Center, United States
The Potential for Condom Ideology to Cloud Clinical Judgment around Prescribing HIV Pre-exposure Prophylaxis (PrEP)
Sarah K. Calabrese
Yale School of Public Health, Yale University, United States
Newly Acquired HIV-1 Infection with Multi-Drug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP
Howard Grossman
Cleveland Clinic, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 04: It Takes Two to Tango: Host, Hormones and Drug Levels in the Mucosa
Pharmacokinetic Analysis of Tenofovir Gel Use in Pre Versus Postmenopausal Women
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Modulation of Tenofovir (TFV) Pharmacokinetics (PK) and Antiviral Activity by Vaginal Microbiota: Implications for Topical Preexposure Prophylaxis
Ekaterina Taneva
Albert Einstein College of Medicine, United States
Hypo-osmolar Formulation of TFV Enemas Promotes Uptake and Transformation of TFV to TFV-DP in Tissues and Prevents SHIV/SIV Infection
Francois Villinger
University of Louisiana at Lafayette, United States
Use of Injectable Depot Medroxyprogesterone Acetate (DMPA) Downregulates Cervicovaginal Epithelial Barrier Genes - Similarly to Mucosal Inflammation
Irina A Zalenskaya
CONRAD, Eastern Virginia Medical School, United States
Microbiome Composition and Function Drives Wound-healing Impairment in the Female Genital Tract
Irene Xie
Public Health Agency of Canada, Canada
MPA Has Minimal Impact on HIV-1 Replication in Ectocervical Tissue Ex Vivo
Hawa Mariko
University of Pittsburgh, United States
from HIV Research for Prevention 2016 on 18 October 2016 10:30-12:00
Oral Abstract Session 05: Risky Business
Behavioral and Biological Risk Factors among MSM in Kigali, Rwanda
Julien Nyombayire
Project San Francisco, Rwanda Zambia HIV Research Group, Rwanda
Meta-analysis and Modelling Study of Anal Sex Practices and Its Contribution to HIV Incidence among High-risk Women Across Twenty US Cities
Jocelyn Elmes
Imperial College London, United Kingdom
A Validated Risk Score to Predict HIV Acquisition in African Women: Assessing Risk Score Performance among Women who Participated in the ASPIRE Trial
Jennifer Balkus
Fred Hutchinson Cancer Research Center, United States
HIV Incidence Factors and Trends in Voluntary Counseling and Testing, Silom Community Clinic, Bangkok, Thailand, 2005-2015
Wipas Wimonsate
Thailand MOPH - U.S. CDC Collaboration, Thailand
Bacterial Vaginosis Associated Microbes Induce Altered Innate Immune Profiles
Ryan Cheu
University of Washington, United States
HIV Treatment Cascade among Transgender Women: Population-estimates from Rio de Janeiro, Brazil
Beatriz Grinsztejn
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 06: Of Mice and (Wo)men: Pharmacokinetics/Pharmacodynamics of Novel Products
Vaginal Transmission of WT or Resistant HIV-1 Was Not Inhibited by Long Acting Rilpivirine at High Plasma and Genital Concentrations in BLT Mice
Zandrea Ambrose
University of Pittsburgh School of Medicine, United States
Pharmacokinetics and Safety of Pod-intravaginal Rings Delivering VRC01-N for HIV Prophylaxis in a Macaque Model
John Moss
Oak Crest Institute of Science, United States
Pharmacokinetic Profile of Lamivudine (3TC) in Macaques and Relative Drug Exposure in Rectal and Vaginal Tissues
Ivana Massud
Centers for Disease Control and Prevention, United States
Comparison of Safety and Pharmacokinetics of Vaginal Rings Releasing Tenofovir Disoproxil Fumarate Alone and with Emtricitabine in Sheep and Humans
Kathleen Vincent
University of Texas Medical Branch, United States
Clinical Performance, Acceptability, and Optimization of Fast-dissolve Vaginal Inserts Designed for HIV-prevention: Results from Two Clinical Studies
Andrea Ries Thurman
CONRAD Eastern Virginia Medical School, United States
Assessment of the Potential for Pharmacodynamic Interaction Between Dapivirine and Levonorgestrel When Co-administered in an MPT Vaginal Ring
Jonathon Holt
International Partnership for Microbicides, United States
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 07: Through the Looking Glass: New Insights into Mucosal Biology
The Role of Gut Homing Receptor α4β7 in HIV Pathogenesis and Transmission - a Prospective Cohort Study
Aida Sivro
Center for AIDS Programme of Research in South Africa, South Africa
Immuno-PET/CT Imaging Reveals Differences in Virus and CD4+ Cell Localization in SIV Infected Rhesus Macaques Treated with an Anti-α4β7 mAb
James Arthos
NIAID, NIH, United States
Multivalent Immunoglobulin Muc5AC Complexes Enhance Antibody Potency Against HIV-1
Arangassery Rosemary Bastian
Northwestern University, United States
Semen Demons: Immunosuppressive Factors Within Semen Modulate Anti-HIV-1 Cellular Immune Responses
Kevin John Selva
University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia
Antiretroviral Therapy Contributes to Intestinal Immune Dysfunction in Healthy Macaques
Alexandra Ortiz
LPD, NIAID, NIH, United States
Initiation of c-ART During HIV Primary Infection Maintains HIV-specific Memory B Cells and Tfh Cells in the Gut Mucosa
Cyril Planchais
INSERM U955, Team 16, Vaccine Research Institute (VRI), France
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Oral Abstract Session 08: A Sugar Coated Pill: Immunogenicity of Envelope
Potent HIV Neutralizing Antibodies Elicited by BG505 SOSIP Trimer Immunization in Rhesus Macaques as a Starting Point for Iterative Vaccine Design
Marit van Gils
Academic Medical Center, University of Amsterdam, Netherlands
Priming a VRC01-like Antibody Response in Human Immunoglobulin Locus Transgenic Mice
Devin Sok
International AIDS Vaccine Initiative (IAVI), United States
Induction of Cross-clade Reactive, Functional Antibodies with Immunogens Targeting the V2 Region of HIV
Rebecca Powell
Icahn School of Medicine at Mount Sinai, United States
Rationally Designed Immunogens Induce Antibody Responses Targeting Polymorphic Forms of gp120 V1V2
Xunqing Jiang
New York University School of Medicine, United States
An Adenovirus 26 Vaccine Expressing Clade A Env (Ad26.EnvA) Does Not Elicit Diversionary gp41-specific Antibodies in Humans
Helen D'Couto
Beth Israel Deaconess Medical Center, United States
MVA-expressed gp140 Boosts More Durable V1/V2 and gp120 Antibody Responses than gp120 Protein in Alum
Xiaoying Shen
Duke Human Vaccine Institute, United States
from HIV Research for Prevention 2016 on 18 October 2016 13:00-14:30
Symposium 01: Vaccine-Induced Humoral Immunity
Initiation of Neutralizing Antibody B Cell Lineages by HIV Vaccine Candidates
Barton Haynes
Duke University, United States
Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers
Christopher Parks
The International AIDS Vaccine Initiative, United States
Towards a Global HIV Vaccine: (Pre)-Clinical Evaluation of Prime-Boost Regimens Using Ad26 and MVA with Mosaic Antigens and Soluble Gp140 Proteins
Hanneke Schuitemaker
Janssen Vaccine and Prevention, Netherlands
Defining Correlates of Protective Humoral Immunity against HIV
Galit Alter
Ragon Institute of MGH, MIT and Harvard, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 02: The Role of Mucosal Barriers and Targets in HIV Acquisition
A Central Role for α4β7+ CD4+ T Cells in HIV Transmission and Pathogenesis
Claudia Cicala
National Institute of Allergy and Infectious Diseases, NIH, United States
Effects of Sex Hormones and Vaginal Microbiota on the Cervicovaginal Mucosal Barrier
Janneke van de Wijgert
University of Liverpool, United Kingdom
Tissue Compartmentalization of Human Immune Responses
Donna Farber
Columbia University Medical Center, United States
Vaginal Bacteria modulate HIV Pre-exposure Prophylaxis Efficacy in Women
Adam Burgener
Public Health Agency of Canada, Canada
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 03: Choosing ARVs for Prevention: Ensuring and Measuring Effective Tissue Delivery
Location, Location, Location: Pharmacology and Tissue Delivery of ARVs
Angela Kashuba
University of North Carolina, United States
Issues with Administration Route as It Relates to Participant Preference, Dosing Strategies, and Coverage Around Times at Risk
Julie Fox
United Kingdom
Pharmacologic Approaches to Assess Adherence
Peter Anderson
University of Colorado, Denver, United States
Linking PK and PD: Choosing Drugs and Predicting Clinical Outcomes Using Data from Explant Models, Animal Models
Jim Turpin
Division of AIDS, NIAID, NIH, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 04: Adolescents: Bodies, Brains and Behaviors
Research Gaps in Understanding Sex Steroid Hormones and Biological and Immunological Features that May Impact Susceptibility to HIV
Sharon L. Achilles
University of Pittsburgh, United States
Promoting Resilience: Understanding Implications of Psychological Development and Decision-making
Susan Rosenthal
Columbia University Medical Center, United States
How to Talk to Me about Sex
Two Youth from Chicago - Kortez Davis and Sydney Roberson
United States
What Interventions Are Suitable for Adolescents?
Chewe Luo
UNICEF, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Plenary 03: Which Way Is Forward: Emerging Challenges and Opportunities
Progress in Neutralizing Antibody-based HIV Vaccine Design
Dennis Burton
The Scripps Research Institute, United States
A View from the Ground
Noel Gordon
Human Rights Campaign, United States
Rings and Things
Sharon Hillier
University of Pittsburgh, United States
from HIV Research for Prevention 2016 on 19 October 2016 08:30-10:00
Oral Abstract Session 09: HIV Antibodies: The Good, the Bad and the Ugly
Characterization of the Early Antibody Landscape in HIV-1 Infected Individuals Who Develop Poor to Elite Levels of Neutralization Breadth
S. Abigail Smith
Emory University, United States
HIV-1 Superinfection Can Lead to Potent Neutralization of the Superinfecting Virus but Is Not Sufficient to Elicit Broadly Neutralizing Antibodies
Daniel J Sheward
University of Cape Town, South Africa
Characterization of Broadly Neutralizing Antibody Responses in HIV-1 Subtype C Infected Children
Zanele Ditse
National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa
The Intrinsic Mutability of Antibody Variable Gene Is Critical for Reproducing Similar Mutation Signatures
Zizhang Sheng
Columbia University Medical Center, United States
Structure of a CH58-like V2 Antibody from Natural Infection Reveals Convergent Heavy Chain Maturation and a Novel K169 Binding Light Chain Motif
Constantinos Kurt Wibmer
National Institute for Communicable Diseases (NHLS), South Africa
Structure of a Natively-glycosylated HIV-1 Env Reveals a New Mode for VH1-2 Antibody Recognition of the CD4 Binding Site Relevant to Vaccine Design
Harry Gristick
Caltech, United States
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 10: Back to the Future: Optimizing the Cascade
Looking at the Whole Picture: The HIV Testing and Care Continuum among Community-recruited MSM, IDU, and Heterosexuals in Washington, DC, 2007-2015
Rudy Patrick
George Washington University Milken Institute School of Public Health, United States
High Uptake of Antiretroviral Treatment among Female Sex Workers in Kigali, Rwanda
Etienne Karita
Project San Francisco, Rwanda
Acceptability of a New Smartphone-based HIV and Syphilis Test to Screen Sexual Partners among High Risk MSM and Transgender Women
Iván Balán
New York State Psychiatric Institute and Columbia University, United States
Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV-positive MSM in Baltimore: Mathematical Modelling for HPTN 078
Kate M. Mitchell
Imperial College London, United Kingdom
Detectable Viral Loads among Those Who Self-report Being Undetectable in the RADAR Cohort of Young MSM - Implications for Treatment as Prevention
Brian Mustanski
Northwestern University, United States
Using Peer Educators to Scale-up HIV Oral Self-testing among Female Sex Workers: An Implementation Science Approach from Kenya
Kipruto Chesang
U.S. Centers for Disease Control and Prevention, Kenya, Kenya
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 11: Testing Vaccine Concepts: Where the Rubber Hits the Road
First-in-human Clinical Trial Evaluating Mosaic HIV-1 Immunogens
Lindsey R Baden
Brigham and Women's Hospital/Harvard Medical School, United States
Optimization of a Pediatric Vaccine to Prevent Breast Milk Transmission of HIV-1
Bonnie Phillips
University of North Carolina at Chapel Hill, United States
DNA and Protein Co-delivery Vaccines Using TLR-4-based Adjuvants Induce Potent Immune Responses Able to Delay Heterologous SIV Acquisition
Barbara K. Felber
National Cancer Institute at Frederick, United States
DNA and Protein Co-administration Elicits Higher HIV-specific nAb and Comparable CD4+ T-cell Responses as Traditional Prime/Boost Regimens (HVTN 105)
Nadine Rouphael
Emory University, United States
Protective Efficacy of Candidate Clinical HIV-1 Vaccine Regimens Against SHIV-SF162P3 Challenges in Rhesus Monkeys
Frank Wegmann
Crucell Holland B.V., a Janssen pharmaceutical company of Johnson & Johnson, Netherlands
Comparing Different Priming Strategies to Optimize HIV Vaccine Antibody Responses: Results from HVTN 096/EV04 (NCT01799954)
Giuseppe Pantaleo
Swiss Vaccine Research Institute, Switzerland
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 12: Pipelines and Platforms for Prevention
Ranpirnase Exhibits Dose-dependent Inhibition of Rectal Explant Infection with HIV-1
Ian McGowan
University of Pittsburgh, United States
Development and Proof-of-Concept Clinical Evaluation of a Freeze-dried Topical Microbicide Insert for On-demand HIV Prevention
Wei Zhang
CONRAD, Eastern Virginia Medical School, United States
Foamed Silicone Intravaginal Rings for Delivery of Macromolecular Therapeutics
Matthew A. Petersen
ProMed Pharma, United States
A Single-reservoir Microbicide Intravaginal Ring for Dual Delivery of Tenofovir and Elvitegravir
Alexander Evanoff
Northwestern University, United States
Evaluation of MK-2048 and Vicriviroc, Formulated as Single or Combination (MK-2048A) Intravaginal Rings, for Development as a Vaginal Microbicide
Charlene Dezzutti
University of Pittsburgh, United States
ECLAIR Study of Cabotegravir LA Injections: Characterization of Safety and PK During the “PK Tail” Phase
Susan Ford
PAREXEL International, United States
from HIV Research for Prevention 2016 on 19 October 2016 10:30-12:00
Oral Abstract Session 13: Do Right to Do Well: Creating a Framework for Success
Harmonization of Regulatory Framework for Control of Clinical Trials in East Africa: Progress, Challenges and Lessons Learnt
Jane Humphrey Mashingia
East African Community Secretariat, Tanzania, United Republic of
Ethics Research to Inform Sexual and Gender Minority Adolescent Participation in HIV Prevention Research
Kathryn Macapagal
Northwestern University, United States
The Journey to GPP Implementation for KAVI Institute of Clinical Research
Jane Ng'ang'a
KAVI-Institute of Clinical research, University of Nairobi, Kenya
Improving the Efficiency of African Research Ethics Committees and Standardizing Ethics Review Processes - Through an Automated Review Platform
Boitumelo Mokgatla
International AIDS Vaccine Initiative (IAVI), Botswana
Toward Innovation in HIV Prevention: Sustaining Funding in a Post-2015 Landscape
Laura Marie Lazar
AVAC: Global Advocacy for HIV Prevention, United States
From Research to Policy to Implementation: A National Plan for Couples' Voluntary HIV Counseling and Testing (CVCT) in Zambia
Susan Allen
Rwanda Zambia HIV Research Group-Emory University, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 14: Teaching the Immune System New Tricks: Vaccine-Induced Immune Responses
Ex Vivo Evaluation of Mucosal Cytokine Responses to in Vivo Vaccination with ALVAC-HIV/AIDSVAX® B/E of Non-human Primates (NHPs) and Humans
Carolina Herrera
Imperial College London, United Kingdom
Vaccine-induced Antibody that Captures but Does Not Neutralize SIVmac251 Increases the Rate of Infection after Low-dose, Repeated Rectal Challenge
Johannes S. Gach
University of California Irvine, United States
NK Cell Changes after a Late Boost with ALVAC-HIV and AIDSVAX® B/E in HIV-Uninfected Thai Adults from RV144
Michael A. Eller
U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States
The Relationship between Immune Responses to Tetanus Vaccine, Hepatitis B Vaccine and a Pox-protein HIV Vaccine Regimen
Ying Huang
Fred Hutchinson Cancer Research Center, United States
Broad HIV-1 Inhibition in Vitro by Vaccine-elicited CD8+ T Cells in African Adults
Josephine Cox
International AIDS Vaccine Initiative (IAVI), United States
Antibody Signature-based Design of HIV-1 Env gp140 Expands Tier 2 Neutralizing Antibody Breadth in Guinea Pigs
Christine Bricault
Beth Israel Deaconess Medical Center, Harvard Medical School, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 15: Unique and Essential: Mucosal Environment of the Female Reproductive Tract
Differences in Genital Tract Immune Cell Populations and Innate Cervicovaginal Fluid Anti-HIV Activity among Women from Zimbabwe and the United States
Sharon L. Achilles
University of Pittsburgh, United States
Very Early Mucosal Responses to Vaginal Infection of SIV
Liang Shang
University of Minnesota, United States
Characterization of Dendritic Cells with Rapid HIV Capture Potential from the Human Female Reproductive Tract
Marta Rodriguez-Garcia
Geisel School of Medicine at Dartmouth, United States
Influence of Sex Hormones and Hormonal Contraceptives on Markers of HIV Risk in the Adolescent Female Genital Tract
Smritee Dabee
University of Cape Town, South Africa
Longitudinal Combined Immunomodulatory Effects of Hormonal Contraceptives and Cervicovaginal Infections in Women Who Did or Did Not HIV Seroconvert
Charles Morrison
FHI 360, United States
Inflammatory Cytokine Responses in the Lower Female Reproductive Tract in Response to Semen
Sinaye Ngcapu
Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Oral Abstract Session 16: PrEP and the Real World
PrEP Initiation and Early Adherence among Young MSM and Transgender Women in Chicago in the Enhancing PrEP in Community (EPIC) Study
Albert Liu
San Francisco Department of Public Health, United States
PrEP Adherence among East African Women with HIV-infected Partners Participating in an Open-label Study
Maria Pyra
University of Washington, United States
PrEP Implementation by Local Health Departments in US Cities and Counties: Findings from a 2015 Assessment of Local Health Departments
Dawn Smith
Centers for Disease Control and Prevention, United States
Women's Knowledge of, Interest in, and Eligibility for HIV Pre-exposure Prophylaxis at Family Planning Clinics in Northern California
Dominika Seidman
University of California San Francisco, United States
Feasibility and Uptake of HIV Self-testing among Adults Visiting Community Pharmacies in Kenya
Peter Mugo
Kemri-Wellcome Trust Research Programme, Kenya
Unplanned Discontinuations of HIV Pre-exposure Prophylaxis During Clinical Care
Douglas Krakower
Beth Israel Deaconess Medical Center, United States
from HIV Research for Prevention 2016 on 19 October 2016 13:00-14:30
Round Table 01: What Is Sterilizing Immunity?
Factors that Impact on the Genotypic and Phenotypic Features of Heterosexually Transmitted Clade C Founder Viruses
Carolyn Williamson
University of Cape Town & NHLS, South Africa
Early Events in HIV-1 Infection: New Insight from the RV217 Early Capture Acute Infection Cohort
Gustavo Kijak
U.S. Military HIV Research Program, Walter Reed Army Insititute of Research, United States
Breakthrough Occult HIV Infections Despite Sustained Plasma Levels of Antiretroviral Drugs Delivered in Long-acting Formulations
Martina Kovarova
University of North Carolina at Chapel Hill, United States
Gp120 Signatures Determining HIV Infectivity Are Universal across Primate Lentiviruses
Mileidy Gonzalez
NCBI, NIH, United States
Neutralizing Antibody-mediated Protection against Mucosal SHIV Challenge Includes Systemic Clearance of Distal Virus
Dan Barouch
Beth Israel Deaconess Medical Center, United States
Round Table Discussion: What Is Sterilizing Immunity?
Carolyn Williamson
University of Cape Town & NHLS, South Africa
Gustavo Kijak
U.S. Military HIV Research Program, Walter Reed Army Insititute of Research, United States
Martina Kovarova
University of North Carolina at Chapel Hill, United States
Mileidy Gonzalez
NCBI, NIH, United States
Dan Barouch
Beth Israel Deaconess Medical Center, United States
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
Round Table 02: The PrEP Prevention Package: From Efficacy Studies to the Real World
Case Studies in PrEP Implementation: The Australian Expanded PrEP Implementation in Communities Study (EPIC-NSW)
Andrew Grulich
Kirby Institute, UNSW Australia, Australia
Pre-Exposure Prophylaxis (PrEP): NYC Implementation Strategy
Demetre Daskalakis
New York City Department of Health and Mental Hygiene, United States
Structural Interventions to Enhance PrEP Availability and Delivery
Nduku Kilonzo
National AIDS Control Council, Kenya
Key Populations and Young People Views and Experiences on PrEP. Messages for Advocacy
Matteo Cassolato
International HIV/AIDS Alliance
Round Table Discussion: The PrEP Prevention Package: From Efficacy Studies to the Real World
Andrew Grulich
Kirby Institute, UNSW Australia, Australia
Demetre Daskalakis
New York City Department of Health and Mental Hygiene, United States
Nduku Kilonzo
National AIDS Control Council, Kenya
Matteo Cassolato
International HIV/AIDS Alliance
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 sessions: 1 to 25 of 42